Original research

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

Theresa Ruf [a,n,1], Rafaela Kramer [b,n,1], Andrea Forschner [c], Ulrike Leiter [c], Friedegund Meier [d], Lydia Reinhardt [d], Pia Dücker [e], Carolin Ertl [a,n,1], Dirk Tomsitz [a], Julia K. Tietze [f], Ralf Gutzmer [g], Evelyn Dabrowski [h], Lisa Zimmer [i], Anja Gesierich [j], Sarah Zierold [a,n,1], Lars E. French [a,l], Thomas Eigentler [k], Teresa Amaral [c,m], Lucie Heinzerling [a,b,n,*,1]

[a] Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany
[b] Department of Dermatology, University Clinic Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
[c] Department of Dermatology, Eberhard-Karls-University of Tübingen, Tübingen, Germany
[d] Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Germany
[e] Department of Dermatology, Hospital Dortmund, Dortmund, Germany
[f] Clinic for Dermatology and Venerology, University Medical Center Rostock, Rostock, Germany
[g] Department of Dermatology, Johannes Wesling Medical Center, Ruhr-University Bochum, Minden, Germany
[h] Clinic Ludwigshafen, Ludwigshafen, Germany
[i] Department of Dermatology, Essen University Hospital, West German Cancer Center, University of Duisburg-Essen and the German Cancer Consortium (DKTK), Partner site Essen/Düsseldorf, Germany
[j] Department of Dermatology, University Hospital Würzburg, Germany
[k] Department of Dermatology, Charité University Medicine Berlin, Berlin, Germany
[l] Dr. Philip Frost Department of Dermatology & Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
[m] Cluster of Excellence iFIT (EXC 2180), Tübingen, Germany
[n] SERIO registry

ARTICLE INFO

ABSTRACT

Background: Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10% of cases. An evidence-based analysis of the effectiveness of second-line immunosuppressive agents with regard to irAE and tumor control is lacking.

Methods: The international web-based Side Effect Registry Immuno-Oncology (SERIO; http://serio-registry.org) is a collaborative initiative with the Paul-Ehrlich-Institute to document rare, severe, complex or therapy-refractory immunotherapy-induced side effects. The registry was queried on August 1, 2023 for cases of irAEs which were treated with second-line therapies.

Results: From a total of 1330 cases, 217 patients (16.3%) received 249 second-line therapies. A total of 19 different second-line therapies were employed, including TNF-alpha antagonists (46.5%), intravenous immunoglobulins (IVIG; 19.1%), mycophenolate mofetil (15.9%), and methotrexate (3.6%). Therapy choices were determined by the type of irAE. The time to onset of sr-/sd-irAEs after ICI initiation did not consistently differ from steroid-responsive irAEs. While 74.3% of sr-/sd-irAEs resolved and 13.1% had improved, 4.3% persisted, 3.9% resulted in permanent sequelae, and 4.3% in death with ongoing symptoms. Infliximab exhibited potential for earlier symptom improvement compared to mycophenolate mofetil or IVIG. Tumor response in patients with second-line treated sd-/sr-irAE was similar to patients with irAEs treated with steroids only.

Conclusion: Several second-line therapies are effective against sr-/sd-irAEs, the second-line therapies show no clear negative impact on tumor response, and infliximab shows potential for faster improvement of symptoms. However, prospective comparative data are needed.

1. Introduction

Due to their effectiveness in many tumor entities immune checkpoint inhibitors (ICIs) are among the most prescribed anti-cancer therapies [1]. However, ICIs also induce immune-related adverse events (irAEs) in all organ systems. While corticosteroids are normally effective in treating irAEs [2,3], a subset of irAEs are steroid-refractory (sr) or steroid-dependent (sd). In sr-irAEs symptoms persist or worsen despite the use of corticosteroids; in sd-irAEs corticosteroids cannot be tapered or discontinued without symptom relapse. The incidence of sr-/sd-irAEs ranges from 2–7% for ICI-treated patients in general [4–6] and can be as high as 14.9% in patients receiving combination therapy with anti-PD1 and anti-CTLA4 antibodies [3] resulting in overall about 10% of cases.

To manage sr-/sd-irAEs, various immunosuppressants are used in combination with or as alternatives to corticosteroids including TNF-α inhibitors, vedolizumab (an $\alpha_4\beta_7$ integrin blocker), anti-interleukin (IL)−6 receptor antibodies (e.g., tocilizumab), anti-IL1, anti-IL17, anti-IL23 agents, anti-thymocyte globulin (ATG), rituximab (an anti-CD20 antibody), abatacept (a CTLA-4 agonist), mycophenolate mofetil, calcineurin inhibitors (e.g., cyclosporine, tacrolimus, sirolimus), cyclophosphamide, methotrexate, leflunomide, azathioprine, and janus kinase inhibitors [7,8]. Additionally, immune modulators like intravenous immunoglobulins (IVIG) and, in rare cases, extracorporeal photopheresis and immunoadsorption have been employed [9–11].

International irAE guidelines like ESMO, ASCO, NCCN or SITC guidelines provide recommendations for first- and second-line therapy of irAEs [12–15], mostly based on past use within clinical studies, retrospective analyses and case reports. Managing sd-/sr-irAEs bears similarities with the treatment of autoimmune diseases. In analogy to colitis ulcerosa treatment, irColitis is often treated with infliximab or vedolizumab, and irArthritis with methotrexate, just like rheumatoid arthritis [16,17]. However, important differences exist between the two scenarios. In autoimmune diseases, immunosuppression aims to downregulate the exaggerated immune response to self-antigens, while in irAEs, immunosuppression needs to strike a balance between controlling the autoimmune response and maintaining an effective antitumor immune response. Furthermore, it is well described that irAEs differ pathogenically from their autoimmune disease counterparts [10,11,18,19]. A more targeted approach to the treatment of irAEs that is based on the key inflammatory components and hopefully also sparing corticosteroids is desirable [7,20]. To date, there is a paucity of prospective data comparing the effectiveness of different second-line treatments for irAEs as well as their influence on tumor control.

With increasing use of ICI, there is a growing need for optimized evidence-based irAE management. We analyzed data from the Side Effect Registry Immuno-Oncology (www.serio-registry.org), an international web-based registry for irAEs that collects rare, severe or therapy-refractory irAEs [21]. By evaluating clinical characteristics, outcomes and effects on sr-/sd-irAEs and tumor response this study aims to provide insights into the use of second-line therapies. The findings of this research may lead to better tailored therapeutic approaches and thus enhance the safety and efficacy of ICI therapy.

2. Methods

The Side Effect Registry Immuno-Oncology (SERIO, www.serio-registry.org), established in partnership with the Paul-Ehrlich-Institute, serves as a comprehensive registry documenting rare, complex, or therapy-refractory side effects linked to immunotherapies including ICI therapies [21]. The registry records irAE cases since 2011. Ethical approval for analyses from the SERIO registry was granted (Erlangen Nr. 2_20 B, Erlangen Nr. 17_16 Bc).

In addition to spontaneously reported cases, seven skin cancer centers in Germany were requested to report their cases of sd-/sr-irAEs to SERIO. SERIO was queried for cases of sr-/sd-irAEs on August 1, 2023. irAEs were defined as adverse events occurring during ICI therapy and deemed immune-related by the treating clinician. The grading of irAEs followed the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Sr-/sd-irAEs encompassed those requiring second-line therapies in addition to corticosteroids. A total of 1330 cases of immune-related adverse events (irAEs) were analyzed for age, gender, tumor type, checkpoint inhibitor type, irAE type, time to irAE onset, second-line therapy type, and irAE outcome. Furthermore, time to irAE improvement, time to irAE resolution, and initial tumor response after commencing second-line immunosuppression were evaluated. The initial tumor response after commencing second-line immunosuppression was defined as the tumor response in the first staging 1–3 months after second-line treatment initiation, to reflect potential effects of second-line therapies on tumor response. Only patients with cutaneous metastatic melanoma were included in the analysis of the tumor response.

Data on time to irAE onset was available for 203/221 (91.9%) and data on irAE outcome was available for 210/221 (95.0%) of cases; time to improvement or resolution of irAEs after initiation of second-line immunosuppression was available for 82/221 (37.1%) and 51/221 (23.1%) patients, respectively. Tumor response data was available for 81 cases of patients with cutaneous metastatic melanoma and second-line therapy for irAEs, and for a control group of 41 patients with cutaneous metastatic melanoma and irAEs responsive to steroids.

Control cohorts of cases with irAEs that showed improvement after administration of steroids and did not require second-line therapies termed steroid-responsive irAEs were generated from the SERIO registry. 397 cases including patients with all tumor entities were analyzed for time to irAE response, and 41 patients with cutaneous metastatic melanoma were analyzed for tumor response.

Statistical analyses were conducted using the Mann-Whitney test for comparison of two groups and One-way Anova for comparison of three groups. MS Excel and GraphPad Prism 9 software were used for graphical representations of data.

3. Results

3.1. Patient characteristics

Out of 1330 cases, 217 patients with a total of 221 sd-/sr-irAEs treated with second-line therapies were analyzed. Among these, 57.5% (127/221) of sd-/sr-irAEs were associated with combined anti-CTLA4 and anti-PD-1 therapy, 34.4% (76/221) with anti-PD-1/PD-L1 monotherapy, and 8.1% (18/221) with anti-CTLA4 monotherapy. The majority of patients were treated for melanoma (203/217; 93.5%; including cutaneous melanoma, mucosal melanoma, conjunctival melanoma, uveal melanoma and melanoma of unknown primary), but the cohort also includes patients with cutaneous squamous cell carcinoma, Merkel cell carcinoma, renal carcinoma, hepatocellular carcinoma, gastric adenocarcinoma, endometrial carcinoma, cervix carcinoma and non-small cell lung cancer (Table 1).

3.2. 19 different second-line therapies were used, most frequently TNF inhibitors

The 217 patients analyzed received a total of 249 second-line therapies for irAEs, including 19 different types or second-line therapies. In most cases, patients were treated with a single second-line therapy, but in 15.6% of cases two subsequent, and in 2.4% of cases three different subsequent second-line therapies were used. In total, 86.4% of sd-/sr-irAE were grade 3 CTCAE or higher. We identified 14 different sd-/sr-irAE types, partly grouped by organ type (Suppl. Table 1), the most common being irColitis (48.3%), irHepatitis (15.6%), hematological irAEs (6.6%), irArthritis (6.1%), and irMyositis (5.2%; Fig. 1b). Second-line therapies included TNF-alpha antagonists (infliximab and adalimumab; 46.5%), intravenous immunoglobulins (IVIG; 19.1%), mycophenolate mofetil (15.9%), and methotrexate (3.6%); extracorporeal

Table 1
Patient characteristics.

n	217
Age – yr	
Median	66
Range	23 - 89
Sex – no. (%)	
Male	124 (57.1%)
Female	93 (42.8%)
Tumor type – no. (%)	
Melanoma	203 (93.5%)
Cutaneous melanoma	120 (55.3%)
Melanoma of unknown primary	26 (12.0%)
Mucosal melanoma	8 (3.7%)
Uveal melanoma	16 (7.4%)
Conjunctival melanoma	1 (0.5%)
Melanoma; not further defined	32 (14.7%)
Cutaneous squamous cell carcinoma	2 (0.9%)
Merkel cell carcinoma	1 (0.5%)
Renal carcinoma	4 (1.8%)
Hepatocellular carcinoma	2 (0.9%)
Gastric adenocarcinoma	1 (0.5%)
Endometrial carcinoma	1 (0.5%)
Cervix carcinoma	1 (0.5%)
Non-small cell lung cancer	2 (0.9%)
Treatment – no. (%)	
Anti-CTLA4 + anti-PD1	*127 (57.5%)*
Ipilimumab + Nivolumab	116 (52.5%)
Ipilimumab + Pembrolizumab	11 (5.0%)
Anti-CTLA4	*18 (8.1%)*
Ipilimumab	18 (8.1%)
Anti-PD-1/-PD-L1	*76 (34.4%)*
Nivolumab	34 (15.4%)
Pembrolizumab	33 (14.9%)
Cemiplimab	2 (0.9%)
Atezolizumab	3 (1.4%)
anti-PD-1; not further defined	4 (1.8%)

photopheresis was used in a minority of cases (0.2%; Fig. 1a). The type of second-line therapies used was associated with the irAE type and the organ system affected (Fig. 1c).

3.3. Most irAEs resolved with second-line therapies

At the last follow-up, 74.3% of irAEs treated with second-line therapies had resolved, 3.9% had resolved with permanent sequelae (Tables 2), 13.1% had improved, 4.3% were unchanged and 4.3% of patients had died with ongoing irAE symptoms (Fig. 2a). Symptom resolution differed depending on the organ system involved and the second-line therapy used (Fig. 2b, c), with irColitis and neurological irAEs having most often sequelae (Table 2). In the case of irHepatitis, the sequelae were persistently elevated liver transaminases. In the patients who died with ongoing symptoms, 37.5% (3/8) of the deaths were due to the irAE, including 1 case of irHepatitis and 2 cases of irEncephalitis.

3.4. Time to onset of steroid-refractory or steroid-dependent irAEs does not consistently differ compared to steroid-responsive irAEs

Time to irAE onset after initiation of ICIs was compared for steroid responsive irAEs and sr-/sd-irAEs for the different irAE types. The time to onset of sr-/sd-irAEs was not significantly different from the time to onset of steroid-responsive irAEs for most irAE types, with the exception of skin-related irAEs and irArthritis. In these cases, sr-/sd-irAEs occurred later than steroid-responsive irAEs (Fig. 3).

3.5. Infliximab showed a trend towards earlier symptom improvement and symptom resolution compared to MMF and IVIG

Time to improvement was defined as the time from initiation of second-line therapy to first significant improvement of laboratory values or symptoms of irAEs. Time to resolution was defined as the time from initiation of second-line therapy to normalization of laboratory values or resolution of clinical symptoms of irAEs. At the time of resolution, some patients were still receiving second-line therapy. The analysis showed a trend towards earlier improvement and resolution of symptoms with infliximab than with mycophenolate mofetil (MMF) or intravenous immunoglobulins (IVIG). It must be noted that the vast majority of patients were treated with infliximab for irColitis and with MMF for irHepatitis (Figs. 4 and 5).

3.6. The association of second-line immunosuppression and tumor response remained inconclusive

Tumor response after second-line immunosuppression was defined as the outcome of the first staging 1–3 months after initiation of the second-line therapy. To ensure data comparability, only patients with metastatic cutaneous melanoma stage IV AJCC were included in this analysis. Progressive disease was seen in 46.1% of patients treated with infliximab and 42.9% of patients treated with MMF, for the other depicted second-line therapies n was ≤ 3. In a control cohort of patients with metastatic cutaneous melanoma stage IV AJCC with steroid-responsive irAEs, progressive disease was observed in 43.9% of patients.

4. Discussion

This study provides valuable insights into the use of second-line therapies for managing sr-/sd-irAEs in patients undergoing ICI treatment by analyzing a large cohort from the Side Effect Registry Immuno-Oncology (SERIO) and 7 additional skin cancer centers. These sr/sd-irAEs occur in 2–7% of ICI patients [4,5].

The use of the 19 different second-line therapies varied depending on the irAE type. Serious outcomes in terms of permanent sequelae or death occurred mainly for specific irAE types including neurologic irAEs, irColitis and irHepatitis. The most commonly administered second-line therapies in our cohort were TNF-alpha antagonists (infliximab and adalimumab; 46.5%), intravenous immunoglobulins (IVIG; 19.1%), mycophenolate mofetil (15.9%), and methotrexate (3.6%). This is comparable to previous studies: in a retrospective single-center study involving 2750 lung cancer patients the predominant treatments utilized were TNF inhibitors (73%) and mycophenolate mofetil (20%) [4]. Similarly, in an analysis of the Dutch Melanoma Treatment Registry TNF inhibitors were the primary treatment choice (71%) [5].

The diverse array of drugs employed in our cohort from 2011–2023 reflects an initial lack of standardized guidelines for managing sr-/sd-irAEs, and the variety recommended by today's guidelines [12,14]. For instance, current guidelines advocate for the use of infliximab or vedolizumab for irColitis, while also suggesting fecal microbiota transplantation, the JAK inhibitor tofacitinib, the IL-12/23 antagonist ustekinumab, or ECP, as these therapies demonstrated successful responses in case reports [12]. While the choice of second-line therapies is often deducted from corresponding autoimmune diseases, it has been shown that irAEs differ from spontaneous autoimmune diseases [10,11, 18,19]. Moreover, considerations such as efficacy in resolving the irAE, potential side effects, and impact on anti-tumor response must be taken into account.

However, retrospective analyses are prone for bias, preclinical data are controversial and data from prospective studies on the effects of second-line immunosuppression for the treatment of sr/sd-irAEs on tumor control is lacking [22].

Among the patients analyzed in this study, 59.2% received combined immunotherapy (anti-PD-1 + anti-CTLA4), in line with previous

findings suggesting higher incidences of irAEs in general [23] as well as sr-/sd-irAEs with combined immunotherapy [3,5]. The most common tumor type was melanoma, as mainly skin cancer centers report to SERIO. Differences in frequency of irAEs by tumor type have been reported, e.g. a higher incidence of irPneumonitis in ICI-treated NSCLC patients which might have contributed to the relatively low number of irPneumonitis cases [24]. Efforts to achieve a more balanced cohort across tumor entities are ongoing [21]. By leveraging the SERIO registry, primarily dedicated to rare and severe irAEs, this study provides unique insight into the use of second-line treatments for rare irAEs including hematological, neurological, and musculoskeletal irAEs. These cannot be analyzed in single-center studies [4,5].

Besides taking into account the comorbidities of the patient, the choice of second-line therapies should be based on the immunological pathways mediating the irAE [25]. For instance, the anti-CD20 antibody rituximab may be used for B-cell mediated irAEs, anti-IL10 antibodies

for anti-IL10 mediated irAEs [7], and anti-IL6 antibodies such as tocilizumab for IL-6 mediated irAEs [20]. Additionally, secondline therapies should not impede tumor control. Unfortunately, the timing, dosage and complex interplay with the immune system have not yielded a uniform picture with regard to the specific effects on tumor response (nicely reviewed in Verheijden, [22]).

Table 2
Steroid-refractory and steroid-dependent irAEs with permanent sequelae and fatal outcome.

irAEs with permanent sequelae (n = 9)	Fatal irAEs (n = 3)
irColitis (4 cases; in 2: hemicolectomy)	irEncephalitis (2 cases)
Guillain-Barré -like Syndrome (2 cases)	irHepatitis
irEncephalitis	
irHepatitis (2 cases)	

Fig. 1. (a:) Second-line therapies employed. Number of second-line therapies used for steroid-refractory / steroid-dependent immune-related adverse events in the cohort. Fig. 1b: Types of irAEs treated with second-line therapies. Number of steroid-refractory / steroid-dependent immune related adverse events (irAEs) by organ type. Fig. 1c: Second-line therapies used depending on irAE type. Number of different second-line therapies used for each type of immune-related adverse event (irAE) in the cohort.

Fig. 2. (a): Outcome of irAEs treated with second-line therapies. *More than one second-line therapy was used for this outcome. irAE: immune-related adverse event; Fig. 2b: Outcome of irAEs treated with second-line therapies by irAE type. *More than one second-line therapy was used for this outcome. irAE: immune-related adverse event. Fig. 2c: Outcome of irAEs treated with second-line therapies by second-line therapy. *The second-line therapy led to the respective outcome when used in combination or sequence with another second-line therapy. irAE: immune-related adverse event.

Infliximab, an anti-TNF-alpha antibody known for its high efficacy in managing irAEs [26,27] which increases the risk of leukopenia, infections and malignancies [28], has a possible negative impact on anti-tumor response to ICI therapy [3,5]. While there have been discussions regarding the hepatotoxicity of infliximab, concrete evidence supporting this claim is lacking.

Mycophenolate mofetil has been successfully administered for

autoimmune hepatitis [29], although it carries a risk of cytopenia, infections [30] and malignancies [31,32]. The impact of MMF on ICI effectiveness and tumor control is unclear. Intravenous immunoglobulins, on the other hand, exhibit diverse immunomodulatory properties, with an exceptionally low incidence of severe adverse events and no association with infections, malignancies or a negative impact on ICI effectiveness [33].

## Time to onset of sr-/sd-irAE and steroid-responsive irAE

Fig. 3. Time to onset of steroid-refractory / -dependent compared to steroid-responsive immune-related adverse events. Time in weeks from initiation of immune checkpoint inhibitor therapy to onset of irAE, for each organ type compared between steroid-responsive irAEs (e.g. Colitis) and steroid-refractory or steroid-dependent irAEs (e.g. sr-/sd-Colitis). Sr-/sd-irAE: Steroid-refractory or seroid-dependent immune related adverse event.

a

Time to improvement of irAE

Breakdown of which irAEs were treated with each second-line therapy	
Infliximab n=50	Colitis n=49 Pneumonitis n=1
MMF n=11	Hepatitis n=8 Nephritis n=1 Myositis n=1 Other gastrointestinal irAE n=1
IVIG n=13	Hepatitis n=3 Blistering skin reactions n=3 Other skin reactions n=2 Colitis n=1 Pancreatic irAE n=1 Myositis n=1 Myocarditis n=1 Hematological irAE n=1
MTX n=3	Arthritis n=3
ECP n=5	Lichenoid skin reactions n=3 Pancreatic irAE n=2

b

Time to resolution of irAE

Breakdown of which irAEs were treated with each second-line therapy	
Infliximab n=36	Colitis n=36
MMF n=8	Hepatitis n=8
IVIG n=2	Blistering skin reactions n=1 Myocarditis n=1
ECP n=5	Lichenoid skin reactions n=2 Pancreatic irAE n=2 Colitis n=1

Fig. 4. (a): Time to improvement of irAE. Time from initiation of second-line therapy to first significant improvement of clinical symptoms or laboratory values and breakdown of cases. MMF: Mycophonalete mofetil, IVIG: Intravenous immunoglobulins, ECP: Extracorporeal photopheresis, irAE: Immune-related adverse event. Fig. 4b: Time to resolution of irAE. Time from initiation of second-line therapy to final resolution of clinical symptoms or normalisation of laboratory values and breakdown of cases. MMF: Mycophonalete mofetil, IVIG: Intravenous immunoglobulins, ECP: Extracorporeal photopheresis, irAE: Immune-related adverse event.

Fig. 5. Tumor response. Tumor response by second-line immunosuppression for patients with metastatic cutaneous melanoma. Only second-line therapies with reported tumor response in at least two cases are shown. The bottom row represents the tumor response of steroid-responsive irAE in patients with metastatic melanoma from the SERIO registry. irAE: immune-related adverse event.

Vedolizumab, an alpha-4-beta-6 integrin inhibitor interfering with lymphocyte trafficking to the gastrointestinal tract, was administered in three cases, all for irColitis. Remarkably, a retrospective analysis of 184 patients (62 vedolizumab, 94 infliximab, 28 combined sequentially) demonstrated that vedolizumab showed similar efficacy to infliximab in treating irColitis, but with the added benefits of better steroid sparing, fewer hospital admissions and, notably, better overall survival [34]. Vedolizumab has not been associated with an increased risk for infection [35].

Methotrexate and hydroxychloroquine were used for rheumatologic irAE such as irMyositis and irArthritis. Methotrexate is frequently employed for irArthritis [17] and does not seem to have an impact on anti-tumor response [36,37], although hepatotoxicity, hematologic toxicity and pulmonary toxicity have been described. Hydroxychloroquine modulates the immune system by hindering autophagy with no known effect on anti-tumor response, but has a slower onset of action and is less effective compared to other options [17].

The anti-IL6 antibody tocilizumab, which inhibits janus kinase (JAK) signal transducer and STAT3, was administered once in our cohort in a case of polymyalgia rheumatica. Tocilizumab has shown effectiveness in managing steroid-refractory irAE [38]. Since IL6 is associated with worse tumor outcome in melanoma patients [39] this could be improving safety and effectiveness. A phase II study is testing the combination of ipilimumab + nivolumab with tocilizumab upfront (NCT03999749) [40].

Extracorporeal photopheresis (ECP) was primarily used for lichenoid skin reactions, following guideline recommendations [41], and for irColitis, supported by a successful case report [9]. ECP has no reported severe side effects [42] and is presumed to have minimal negative impact on tumor response, as suggested by observations in lymphoma patients [43,44].

In isolated cases, rituximab, plasmapheresis, tacrolimus, sirolimus, cyclosporin A, cyclophosphamid, alemtuzumab, anti-thymocyte globuline, acitretine, and sandostatin were used.

Remarkably, in this cohort, the drugs vedolizumab and tocilizumab were only employed in a minority of cases (1.2% and 0.4%, respectively), despite their potential advantages in terms of anti-tumor response compared to other second-line therapies. This may be partly due to the high cost of those relatively new medications, even though in a study overall cost savings could be shown by administering tocilizumab when infliximab would have been an alternative option [38].

The major limitation of this study is its retrospective nature with voluntary reporting. Prospective data comparing second-line therapies is currently lacking, although it is highly relevant to assess the most effective treatment strategies and fully understand the impact on tumor response. However, prospective studies are ongoing to address this gap in knowledge including one at our center (NCT05700565).

Despite frequent resolution of sr-/sd-irAEs with second-line treatments, 3.9% of irAEs resulted in permanent sequelae, most commonly

irColitis and neurological irAEs, and 3 sr/sd-irAEs resulted in death including 2 cases of encephalitis and 1 case of hepatitis. Our data show that sr-/sd-irAEs can affect a variety of organ systems and include rare irAEs such as hematological irAEs and neurologic irAEs. Morbidity and mortality of rare irAEs is known to be high [10,11,45], thus, identifying the most effective second-line therapy is crucial. However, since these events are rare, only single cases appear in small patient cohorts and joint efforts must be made to better analyze them.

The time to onset of sr-/sd-irAEs did not consistently differ from that of steroid-responsive irAEs within each irAE type. This suggests that rapidity of onset of irAEs is likely not a reliable predictor of irAE refractoriness or dependence on steroids.

The time to improvement or resolution of symptoms following initiation of second-line immunosuppression is a crucial consideration in managing irAEs. Our analysis demonstrated a trend towards earlier improvement and resolution of symptoms with infliximab compared to mycophenolate mofetil or IVIG, even though this may be biased since infliximab was primarily used for irColitis and mycophenolate mofetil primarily for irHepatitis. Due to data constraints, we were unable to assess concurrent steroid usage or cumulative steroid doses.

Understanding the impact of second-line therapies on tumor response is of great importance. 46.1% of infliximab-treated patients and 42.9% of mycophenolate mofetil-treated patients with metastatic cutaneous melanoma showed progressive disease 1–3 months after second-line therapy initiation. This is comparable to steroid-responsive patients which showed progressive disease in 43.9%. It is also comparable to a retrospective cohort of patients treated with steroids for irAE; here, progressive disease was observed in about 50% in patients with early steroid administration and in < 10% in patients with late steroid administration (more than 4 weeks after ICI initiation) [46]. To ensure a higher level of follow-up on tumor response data automatic reminders have been established in the SERIO database and initiatives to enlarge the non-melanoma cohort have been undertaken. In a previous study, the addition of second-line immunosuppressants to steroid therapy (TNF inhibitors n = 67, mycophenolate mofetil n = 10, tacrolimus n = 1, non-specified n = 24) compared to corticosteroids alone was linked to reduced overall survival, increased risk of tumor progression, and higher mortality in patients with advanced melanoma [3]. However, these findings are in contrast to a study involving 27 ICI-treated melanoma patients who developed irColitis and received TNF inhibitor treatment, and demonstrated a median progression-free survival of 3 months, aligning with findings from earlier studies of ICI-treated melanoma patients without TNF inhibitor treatment. Similarly, a retrospective analysis of patients with ICI-induced colitis revealed no significant disparity in overall survival between those treated solely with corticosteroids (n = 38) and those receiving a combination of corticosteroids and a TNF inhibitor (n = 23) (p = 0.263) [27]. First results from a prospective phase Ib clinical trial investigating the potential of combining infliximab or certolizumab with a combined immunotherapy regimen with

ipilimumab and nivolumab show safety of both combinations and a high tumor response rate in the certolizumab-treated patient cohort [47]. Further research is warranted to explore the interplay between immune-related toxicities, immunosuppression, and antitumor efficacy.

Overall, this study provides important insights into the management of sr-/sd-irAEs including rare irAEs. The findings underscore the complexity and heterogeneity of irAEs, highlighting the need for prospective studies, registries such as SERIO and individualized approaches.

Funding

CRediT authorship contribution statement

Teresa Amaral: Writing – review & editing, Data curation. **Pia Dücker:** Writing – review & editing, Data curation. **Lucie Heinzerling:** Writing – review & editing, Writing – original draft, Supervision, Formal analysis, Data curation, Conceptualization. **Carolin Ertl:** Writing – review & editing, Data curation. **Friedegund Meier:** Writing – review & editing, Data curation. **Lars E. French:** Writing – review & editing. **Thomas Eigentler:** Writing – review & editing, Data curation. **Lydia Reinhardt:** Writing – review & editing, Data curation. **Sarah Zierold:** Writing – review & editing, Data curation. **Ulrike Leiter:** Writing – review & editing, Data curation. **Lisa Zimmer:** Writing – review & editing, Data curation. **Rafaela Kramer:** Writing – review & editing, Data curation. **Anja Gesierich:** Writing – review & editing, Data curation. **Andrea Forschner:** Writing – review & editing, Data curation. **Ralf Gutzmer:** Writing – review & editing, Data curation. **Evelyn Dabrowski:** Data curation. **Theresa Ruf:** Writing – original draft, Visualization, Formal analysis, Data curation. **Dirk Tomsitz:** Writing – review & editing, Data curation. **Julia K. Tietze:** Writing – review & editing, Data curation.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.ejca.2024.114028.

References

[1] Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. 2020 11:1 Nat Commun 2020;11:1–3. https://doi.org/10.1038/s41467-020-17670-y.
[2] Bai X, Hu J, Warner AB, Quach HT, Cann CG, Zhang MZ, et al. Early use of high-dose glucocorticoid for the management of irae is associated with poorer survival in patients with advanced melanoma treated with Anti-PD-1 monotherapy. Clin Cancer Res 2021;27:5993–6000. https://doi.org/10.1158/1078-0432.CCR-21-1283.
[3] van Not OJ, Verheijden RJ, van den Eertwegh AJM, Haanen JBAG, Aarts MJB, van den Berkmortel FWPJ, et al. Association of immune-related adverse event management with survival in patients with advanced Melanoma. JAMA Oncol 2022. https://doi.org/10.1001/JAMAONCOL.2022.5041.
[4] Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, et al. Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events. J Thorac Oncol 2021;16:1759–64. https://doi.org/10.1016/j.jtho.2021.06.024.
[5] Verheijden, May RJ, Blank AM, Aarts CU, Berkmortel MJB, Den FWPJV, Eertwegh, Den AJMV, et al. Association of Anti-TNF with decreased survival in steroid refractory Ipilimumab and Anti-PD1-treated patients in the dutch melanoma treatment registry. Clin Cancer Res 2020;26:2268–74. https://doi.org/10.1158/1078-0432.CCR-19-3322.
[6] Tomsitz D, Ruf T, Zierold S, French LE, Heinzerling L. Steroid-refractory immune-related adverse events induced by checkpoint inhibitors. Cancers (Basel) 2023;15: 2538. https://doi.org/10.3390/CANCERS15092538.
[7] Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol 2019;20:e54–64. https://doi.org/10.1016/S1470-2045(18)30828-3.
[8] Wang A, Xu Y, Fei Y, Wang M. The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. Asia Pac J Clin Oncol 2020;16:201–10. https://doi.org/10.1111/AJCO.13332.
[9] Apostolova P, Unger S, von Bubnoff D, Meiss F, Becher B, Zeiser R. Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy. N Engl J Med 2020;382:294–6. https://doi.org/10.1056/NEJMC1912274/SUPPL_FILE/NEJMC1912274_DISCLOSURES.PDF.
[10] Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, et al. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data Brief 2022;45. https://doi.org/10.1016/J.DIB.2022.108649.
[11] Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:12–23. https://doi.org/10.1016/J.EJCA.2018.09.033.
[12] Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann Oncol 2022;0. https://doi.org/10.1016/J.ANNONC.2022.10.001.
[13] Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN clinical practice guidelines in oncology nccn categories of evidence and consensus. J Natl Compr Canc Netw 2019;17:255–89. https://doi.org/10.6004/jnccn.2019.0013.
[14] Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39: 4073–126. https://doi.org/10.1200/JCO.21.01440.
[15] Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9. https://doi.org/10.1136/JITC-2021-002435.
[16] Hashash JG, Francis FF, Farraye FA. Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol Hepatol (N Y) 2021;17:358.
[17] Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. Autoimmun Rev 2020;19:102595. https://doi.org/10.1016/J.AUTREV.2020.102595.
[18] Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, et al. Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid. J Eur. Acad Dermatol Venereol 2024. https://doi.org/10.1111/JDV.19860.
[19] Meier-Schiesser B, Zecha C, Zierold S, Kolm I, Röckel M, Fröhlich W, et al. Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological and gene expression level. JAAD Int 2024;0. https://doi.org/10.1016/j.jdin.2023.11.013.
[20] Husain B, Kirchberger MC, Erdmann M, Schüpferling S, Abolhassani AR, Fröhlich W, et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol 2021;147:1623–30. https://doi.org/10.1007/S00432-021-03550-5.
[21] Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon M von, et al. The Side Effect Registry Immuno-Oncology (SERIO) – a tool for systematic analysis of immunotherapy-induced side effects. Eur J Cancer 2023;0:113505. https://doi.org/10.1016/J.EJCA.2023.113505.
[22] Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol 2023;7. https://doi.org/10.1038/S41698-023-00380-1.
[23] Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345. https://doi.org/10.1056/NEJMOA1709684.
[24] Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 2018;13:1930–9. https://doi.org/10.1016/J.JTHO.2018.08.2035.
[25] Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, et al. Original research: systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2022;10:5635. https://doi.org/10.1136/JITC-2022-005635.
[26] Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, et al. Incidence and Clinical Impact of Anti-TNFα treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the mecolit survey. J Immunother 2019;42: 175–9. https://doi.org/10.1097/CJI.0000000000000268.
[27] Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheuma 2021;17:213. https://doi.org/10.1038/S41584-021-00584-4.
[28] Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in

randomized controlled trials. JAMA 2006;295:2275–85. https://doi.org/10.1001/JAMA.295.19.2275.

[29] Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011;55:636–46. https://doi.org/10.1016/J.JHEP.2010.12.032.

[30] Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001;10: 606–11. https://doi.org/10.1191/096120301682430186.

[31] Pundole X, Suarez-Almazor ME. Cancer and rheumatoid arthritis. Rheum Dis Clin North Am 2020;46:445–62. https://doi.org/10.1016/J.RDC.2020.05.003.

[32] Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005;65:639–41. https://doi.org/10.1212/01.WNL.0000173031.56429.04.

[33] Brennan VM, Salomé-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003;133:247–51. https://doi.org/10.1046/J.1365-2249.2003.02199.X.

[34] Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 2021;9. https://doi.org/10.1136/JITC-2021-003277.

[35] Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017;66: 839–51. https://doi.org/10.1136/GUTJNL-2015-311079.

[36] Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 2018;4:e000714. https://doi.org/10.1136/RMDOPEN-2018-000714.

[37] Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 2020;79:332–8. https://doi.org/10.1136/ANNRHEUMDIS-2019-216109.

[38] Stroud CRG, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pr 2019;25:551–7. https://doi.org/10.1177/1078155217745144.

[39] Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer 2020;8. https://doi.org/10.1136/JITC-2020-000842.

[40] Weber JS, Muramatsu T, Hamid O, Mehnert J, Hodi FS, Krishnarajapet S, et al. 1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma. Ann Oncol 2021;32:S869. https://doi.org/10.1016/j.annonc.2021.08.1425.

[41] Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, et al. European dermatology forum: updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2. J Eur Acad Dermatol Venereol 2021;35:27–49. https://doi.org/10.1111/JDV.16889.

[42] Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, et al. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur. Acad Dermatol Venereol 2020;34:2693–716. https://doi.org/10.1111/JDV.16890.

[43] Wang L, Ni M, Hückelhoven-Krauss A, Sellner L, Hoffmann JM, Neuber B, et al. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-host disease without hampering anti-viral/Anti-leukemic Effects. Front Immunol 2018;9. https://doi.org/10.3389/FIMMU.2018.02207.

[44] Flinn AM, Gennery AR. Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation. F1000Res 2016;5. https://doi.org/10.12688/F1000RESEARCH.8118.1.

[45] Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer 2021;147:170–81. https://doi.org/10.1016/J.EJCA.2021.01.013.

[46] Bar-Hai N, Ben-Betzalel G, Stoff R, Grynberg S, Schachter J, Shapira-Frommer R, et al. Better late than never: the impact of steroidal treatment on the outcome of melanoma patients treated with immunotherapy. Cancers (Basel) 2023;15. https://doi.org/10.3390/CANCERS15113041.

[47] Montfort A, Filleron T, Virazels M, Dufau C, Milhes J, Pages C, et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res 2021;27:1037–47. https://doi.org/10.1158/1078-0432.CCR-20-3449.